Muthiah Vaduganathan, MD, MPH, cardiologist at Brigham and Women’s Hospital recently cowrote a special report for the New England Journal of Medicine about the use of renin-angiotensin-aldosterone system (RAAS) inhibitors in patients infected with COVID-19.

As Dr. Vaduganathan explains in this video, there is preclinical data to indicate an interaction may exist between these antihypertensive agents and the coronavirus but until proper clinical studies have been performed, it is too early to tell whether the use of these agents in people with high blood pressure should be withheld.

In their report, Vaduganathan et al state “On the basis of the available evidence, we think that, despite the theoretical concerns and uncertainty regarding the effect of RAAS inhibitors on ACE2 and the way in which these drugs might affect the propensity for or severity of Covid-19, RAAS inhibitors should be continued in patients in otherwise stable condition who are at risk for, are being evaluated for, or have Covid-19.”

Be sure to follow us on twitter for more COVID-19 updates.

  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.